Department of Health and Human Services (HHS): NAICS 325413 — In-Vitro Diagnostic Substance Manufacturing

2open solicitations
$12.8Mobligated in FY2026
60contracts ending within 18 months

Open solicitations

Open any solicitation for a free AI read of its package — deal-breakers and risks, each quoted from the page it came from. With a free account, FedSift also builds its compliance matrix.

How HHS NAICS 325413 spends

FY2021$31.2M
FY2022$85.7M
FY2023$1.2B
FY2024$49.1M
FY2025$20.9M
FY2026$12.8M
FY2027*$420K

Contract obligations by federal fiscal year (October–September), from USASpending.gov award data. IDIQ ceilings are excluded. * The current year is partial, and USASpending lags 4–8 weeks.

HHS NAICS 325413 contracts expiring in the next 18 months

60 contracts worth $47.2M.

IncumbentBuyerWhatValueEndsEst. solicitationRecord
BECTON, DICKINSON AND COMPANYIHS325413 In-Vitro Diagnostic Substance Manufacturing$102K30 November 2026Now / imminentDetails
10X GENOMICS, INC.NIH325413 In-Vitro Diagnostic Substance Manufacturing$37K08 December 2026Now / imminentDetails
QIAGEN, LLCFDA325413 In-Vitro Diagnostic Substance Manufacturing$35K14 December 2026Now / imminentDetails
RED HERITAGE MEDICAL DIAGNOSTICS COMPANY LLCIHS325413 In-Vitro Diagnostic Substance Manufacturing$49K31 December 2026Now / imminentDetails
CEPHEIDIHS325413 In-Vitro Diagnostic Substance Manufacturing$460K11 January 2027Now / imminentDetails
10X GENOMICS, INC.NIH325413 In-Vitro Diagnostic Substance Manufacturing$46K (2 orders)22 January 2027Now / imminentDetails
HARDY DIAGNOSTICSIHS325413 In-Vitro Diagnostic Substance Manufacturing$37K22 January 2027Now / imminentDetails
WERFEN USA LLCIHS325413 In-Vitro Diagnostic Substance Manufacturing$224K31 January 2027Now / imminentDetails
WERFEN USA LLCNIH325413 In-Vitro Diagnostic Substance Manufacturing$170K31 January 2027Now / imminentDetails
BIOMERIEUX INCIHS325413 In-Vitro Diagnostic Substance Manufacturing$240K26 February 2027Now / imminentDetails
BIOSEARCH TECHNOLOGIES, INC.CDC325413 In-Vitro Diagnostic Substance Manufacturing$40K27 February 2027Now / imminentDetails
CEPHEIDIHS325413 In-Vitro Diagnostic Substance Manufacturing$2.8M28 February 2027Now / imminentDetails
CEPHEIDIHS325413 In-Vitro Diagnostic Substance Manufacturing$312K (2 orders)28 February 2027Now / imminentDetails
ABBOTT LABORATORIES INC.IHS325413 In-Vitro Diagnostic Substance Manufacturing$310K28 February 2027Now / imminentDetails
INVIVOSCRIBE, INC.NIH325413 In-Vitro Diagnostic Substance Manufacturing$57K04 March 2027Now / imminentDetails

Contracts and task orders from USASpending.gov (FPDS) whose period of performance ends within 18 months, valued at $25K or more, excluding IDIQ ceilings and government-owned, contractor-operated facility contracts. Co-terminous orders from the same vendor, agency, NAICS and PSC ending in the same month are grouped. The solicitation date is an estimate (about six months before the contract ends): FedSift does not know whether a follow-on has been posted, so check SAM.gov.

NAICS 325413 across every agency → · Everything HHS has open →

FedSift turns SAM.gov and USASpending data into federal BD intelligence — smart matches, recompete radar, cited AI solicitation analysis and compliance matrices.

Source data: SAM.gov (solicitations) and USASpending.gov (awards), refreshed nightly. FedSift is not affiliated with the U.S. Government.

Pricing · Privacy · Terms · support@fedsift.app